Cytokine networking of innate immunity cells: A potential target of therapy

Clinical Science

Volumn 126, Issue 9, 2014, Pages 593-612

  Striz, Ilja ^a,b   Brabcova, Eva ^a   Kolesar, Libor ^a   Sekerkova, Alena ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

biologics; cytokine; immunomodulation; mucosal immunity

Indexed keywords

ADAPTIVE IMMUNITY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION;

EID: 84893938074     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130497     Document Type: Review

References (292)

1. Bulek, K., Swaidani, S., Aronica, M. and Li, X. (2010) Epithelium: the interplay between innate and Th2 immunity. Immunol. Cell Biol. 88, 257-268.
2. Lambrecht, B. N. and Hammad, H. (2012) The airway epithelium in asthma. Nat. Med. 18, 684-692.
3. Szabady, R. L. and McCormick, B. A. (2013) Control of neutrophil inflammation at mucosal surfaces by secreted epithelial products. Front. Immunol. 4, 220.
4. Thorburn, E., Kolesar, L., Brabcova, E., Petrickova, K., Petricek, M., Jaresova, M., Slavcev, A. and Striz, I. (2009) CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines. APMIS 117, 477-487.
5. Striz, I., Slavcev, A., Kalanin, J., Jaresova, M. and Rennard, S. I. (2001) Cell-cell contacts with epithelial cells modulate the phenotype of human macrophages. Inflammation 25, 241-246.
6. Wilkinson, R., Wang, X., Roper, K. E. and Healy, H. Activated human renal tubular cells inhibit autologous immune responses. (2011) Nephrol. Dial. Transplant. 26, 1483-1492.
7. Vitalone, M. J., Naesens, M., Sigdel, T., Li, L., Hseih, S. and Sarwal, M. M. (2011) The dual role of epithelial-tomesenchymal transition in chronic allograft injury in pediatric renal transplantation. Transplantation 92, 787-795.
8. Danese, S. (2008) Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol. 29, 555-564.
9. Holgate, S. T., Arshad, H. S., Roberts, G. C., Howarth, P. H., Thurner, P. and Davies, D. E. (2009) A new look at the pathogenesis of asthma. Clin. Sci. 118, 439-450.
10. Nguan, C. Y. and Du, C. (2009) Renal tubular epithelial cells as immunoregulatory cells in renal allograft rejection. Transplant. Rev. 23, 129-138.
11. ++) monocytes and regular monocytes in human blood. Pathobiology 59, 127-130.
12. + cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur. J. Immunol. 30, 1872-1883.
13. + monocytes exhibit proinflammatory and proatherosclerotic activity. J. Immunol. 186, 1809-1815.
14. + monocytes are a major source of TNF. J. Immunol. 168, 3536-3542.
15. Li, J., Pritchard, D. K., Wang, X., Park, D. R., Bumgarner, R. E., Schwartz, S. M. and Liles, W. C. (2007) cDNA microarray analysis reveals fundamental differences in the expression profiles of primary human monocytes, monocyte-derived macrophages, and alveolar macrophages. J. Leukoc. Biol. 81, 328-335.
16. Devaraj, S. and Jialal, I. (2011) C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler. Thromb. Vasc. Biol. 31, 1397-1402.
17. Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart, D. N., Leenen, P. J. M., Liu, Y. J., MacPherson, G., Randolph, G. J. et al. (2010) Nomenclature of monocytes and dendritic cells in blood. Blood 116, E74-E80.
18. Reschner, A., Hubert, P., Delvenne, P., Boniver, J. and Jacobs, N. (2008) Innate lymphocyte and dendritic cell crosstalk: a key factor in the regulation of the immune response. Clin. Exp. Immunol. 152, 219-226.
19. + DC are a heterogeneous population with distinct functions. Immunology 135, 75-75.
20. Borregaard, N., Sorensen, O. E. and Theilgaard-Wnchl, K. (2007) Neutrophil granules: a library of innate immunity proteins. Trends Immunol 28, 340-345.
21. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y. and Zychlinsky, A. (2004) Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535.
22. Kovach, M. A. and Standiford, T. J. (2012) The function of neutrophils in sepsis. Curr. Opin. Infect. Dis. 25, 321-327.
23. Schroder, A. K., von der Ohe, M., Kolling, U., Altstaedt, J., Uciechowski, P., Fleischer, D., Dalhoff, K., Ju, X., Zenke, M., Heussen, N. and Rink, L. (2006) Polymorphonuclear leucocytes selectively produce anti-inflammatory interleukin-1 receptor antagonist and chemokines, but fail to produce pro-inflammatory mediators. Immunology 119, 317-327.
24. Li, L., Huang, L., Vergis, A. L., Ye, H., Bajwa, A., Narayan, V., Strieter, R. M., Rosin, D. L. and Okusa, M. D. (2010) IL-17 produced by neutrophils regulates IFN-γ -mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J. Clin. Invest. 120, 331-342.
25. Gebreselassie, N. G., Moorhead, A. R., Fabre, V., Gagliardo, L. F., Lee, N. A., Lee, J. J. and Appleton, J. A. (2012) Eosinophils preserve parasitic nematode larvae by regulating local immunity. J. Immunol. 188, 417-425.
26. Holgate, S. T. (2008) Pathogenesis of asthma. Clin. Exp. Allergy 38, 872-897.
27. Zagai, U., Lundahl, J., Klominek, J., Venge, P. and Skold, C. M. (2009) Eosinophil cationic protein stimulates migration of human lung fibroblasts in vitro. Scand. J. Immunol. 69, 381-386.
28. Oyoshi, M. K., He, R., Kanaoka, Y., ElKhal, A., Kawamoto, S., Lewis, C. N., Austen, K. F. and Geha, R. S. (2012) Eosinophil-derived leukotriene C4 signals via type 2 cysteinyl leukotriene receptor to promote skin fibrosis in a mouse model of atopic dermatitis. Proc. Natl. Acad. Sci. U.S.A. 109, 4992-4997.
29. Ogbogu, P. U., Rosing, D. R. and Horne, III, M. K. (2007) Cardiovascular manifestations of hypereosinophilic syndromes. Immunol. Allergy Clin. North. Am. 27, 457-475.
30. Pasha, S. F., Sharma, V. K. and Crowell, M. D. (2006) Current concepts and treatment options in eosinophilic esophagitis. Curr. Opin. Investig. Drugs 7, 992-996.
31. Cho, S. H., Seo, J. Y., Choi, D. C., Yoon, H. J., Cho, Y. J., Min, K. U., Lee, G. K., Seo, J. W. and Kim, Y. Y. (1996) Pathological changes according to the severity of asthma. Clin. Exp. Allergy 26, 1210-1219.
32. Moosbauer, C., Morgenstern, E., Cuvelier, S. L., Manukyan, D., Bidzhekov, K., Albrecht, S., Lohse, P., Patel, K. D. and Engelmann, B. (2007) Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 109, 995-1002.
33. Florian, S., Sonneck, K., Czerny, M., Hennersdorf, F., Hauswirth, A. W., Buhring, H. J. and Valent, P. (2006) Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy 61, 1054-1062.
34. Arinobu, Y., Iwasaki, H., Gurish, M. F., Mizuno, S., Shigematsu, H., Ozawa, H., Tenen, D. G., Austen, K. F. and Akashi, K. (2005) Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc. Natl. Acad. Sci. U.S.A. 102, 18105-18110.
35. Karasuyama, H., Obata, K., Wada, T., Tsujimura, Y. and Mukai, K. (2011) Newly appreciated roles for basophils in allergy and protective immunity. Allergy 66, 1133-1141.
36. Shin, K., Nigrovic, P. A., Crish, J., Boilard, E., McNeil, H. P., Larabee, K. S., Adachi, R., Gurish, M. F., Gobezie, R., Stevens, R. L. and Lee, D. M. (2009) Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J. Immunol. 182, 647-656.
37. Groot Kormelink, T., Abudukelimu, A. and Redegeld, F. A. (2009) Mast cells as target in cancer therapy. Curr. Pharm. Des. 15, 1868-1878.
38. de Vries, V. C., Elgueta, R., Lee, D. M. and Noelle, R. J. (2010) Mast cell protease 6 is required for allograft tolerance. Transplant. Proc. 42, 2759-2762.
39. Ito, Y., Satoh, T., Takayama, K., Miyagishi, C., Walls, A. F. and Yokozeki, H. (2011) Basophil recruitment and activation in inflammatory skin diseases. Allergy 66, 1107-1113.
40. Brodin, P., Lakshmikanth, T., Karre, K. and Hoglund, P. (2012) Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets. J. Immunol. 188, 2218-2226.
41. Sun, J. C., Lopez-Verges, S., Kim, C. C., DeRisi, J. L. and Lanier, L. L. (2011) NK cells and immune "memory". J. Immunol. 186, 1891-1897.
42. Arrenberg, P., Halder, R., Dai, Y., Maricic, I. and Kumar, V. (2010) Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a ß-linked self-glycolipid. Proc Natl. Acad. Sci. U.S.A. 107, 10984-10989.
43. + lymphoid cells. Nature 463, 540-544.
44. Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T. K., Bucks, C., Kane, C. M., Fallon, P. G., Pannell, R. et al. (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370.
45. Price, A. E., Liang, H. E., Sullivan, B. M., Reinhardt, R. L., Eisley, C. J., Erle, D. J. and Locksley, R. M. (2010) Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc. Natl. Acad. Sci. U.S.A. 107, 11489-11494.
46. H2 cytokine responses. Nature 464, 1362-1366.
47. Spits, H. and Di Santo, J. P. (2011) The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12, 21-27.
48. Yang, D., de la Rosa, G., Tewary, P. and Oppenheim, J. J. (2009) Alarmins link neutrophils and dendritic cells. Trends Immunol. 30, 531-537.
49. Yano, J., Noverr, M. C. and Fidel, Jr, P. L. (2012) Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins. Cytokine 58, 118-128.
50. Semple, F. and Dorin, J. R. (2012) ß-defensins: multifunctional modulators of infection, inflammation and more? J. Innate Immun. 4, 337-348.
51. Shirin, T., Rahman, A., Danielsson, A., Uddin, T., Bhuyian, T. R., Sheikh, A., Qadri, S. S., Qadri, F. and Hammarstrom, M. L. (2011) Antimicrobial peptides in the duodenum at the acute and convalescent stages in patients with diarrhea due to Vibrio cholerae O1 or enterotoxigenic Escherichia coli infection. Microbes Infect. 13, 1111-1120.
52. Pennings, J. L., Schuurhof, A., Hodemaekers, H. M., Buisman, A., de Rond, L. C., Widjojoatmodjo, M. N., Luytjes, W., Kimpen, J. L., Bont, L. and Janssen, R. (2011) Systemic signature of the lung response to respiratory syncytial virus infection. PLoS ONE 6, e21461.
53. Yanai, H., Chiba, S., Ban, T., Nakaima, Y., Onoe, T., Honda, K., Ohdan, H. and Taniguchi, T. (2011) Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc. Natl. Acad. Sci. U.S.A. 108, 11542-11547.
54. Stenger, S., Hanson, D. A., Teitelbaum, R., Dewan, P., Niazi, K. R., Froelich, C. J., Ganz, T., Thoma-Uszynski, S., Melian, A., Bogdan, C. et al. (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121-125.
55. Curran, C. S. and Bertics, P. J. (2012) Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1a and MCP-1 in GM-CSF-treated human primary eosinophils. J. Interferon Cytokine Res. 30, 450-461.
56. Srikrishna, G. and Freeze, H. H. (2009) Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11, 615-628.
57. Gougeon, M. L., Melki, M. T. and Saidi, H. (2012) HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells. Cell Death Diff. 19, 96-106.
58. Aggarwal, B. B., Gupta, S. C. and Kim, J. H. (2012) Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119, 651-665.
59. Zheng, L., Teschler, H., Guzman, J., Hubner, K., Striz, I. and Costabel, U. (1995) Alveolar macrophage TNF-α release and BAL cell phenotypes in sarcoidosis. Am. J. Respir. Crit. Care Med. 152, 1061-1066.
60. Park, H., Park, S. G., Kim, J., Ko, Y. G. and Kim, S. (2002) Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. Cytokine 20, 148-153.
61. Tracey, K. J., Lowry, S. F. and Cerami, A. (1988) Cachectin: a hormone that triggers acute shock and chronic cachexia. J. Infect. Dis. 157, 413-420.
62. Leon, L. R., White, A. A. and Kluger, M. J. (1998) Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol. 275, R269-R277.
63. Plomgaard, P., Fischer, C. P., Ibfelt, T., Pedersen, B. K. and van Hall, G. (2008) Tumor necrosis factor-α modulates human in vivo lipolysis. J. Clin. Endocrinol. Metab. 93, 543-549.
64. Patel, J. N., Jager, A., Schalkwijk, C., Corder, R., Douthwaite, J. A., Yudkin, J. S., Coppack, S. W. and Stehouwer, C. D. (2002) Effects of tumour necrosis factor-α in the human forearm: blood flow and endothelin-1 release. Clin. Sci. 103, 409-415.
65. Nawroth, P. P. and Stern, D. M. (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163, 740-745.
66. Ijzerman, R. G., Voordouw, J. J., Van Weissenbruch, M. M., Yudkin, J. S., Serne, E. H., Delemarre-van de Waal, H. A. and Stehouwer, C. D. (2006) TNF-α levels are associated with skin capillary recruitment in humans: a potential explanation for the relationship between TNF-α and insulin resistance. Clin. Sci. 110, 361-368.
67. Smolen, J. S., Aletaha, D. and Redlich, K. (2012) The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat. Rev. Rheumatol. 8, 235-243.
68. Hansen, R., Thomson, J. M., El-Omar, E. M. and Hold, G. L. (2010) The role of infection in the aetiology of inflammatory bowel disease. J. Gastroenterol. 45, 266-276.
69. Guilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F. X., Lecron, J. C. and Morel, F. (2010) Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1 a, and TNF-α recapitulates some features of psoriasis. J. Immunol. 184, 5263-5270.
70. de Godoy, I., Donahoe, M., Calhoun, W. J., Mancino, J. and Rogers, R. M. (1996) Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. 153, 633-637.
71. Roman, J., Fernandez, F., Velasco, F., Rojas, R., Roldan, M. R. and Torres, A. (1993) Serum TNF levels in neonatal sepsis and septic shock. Acta Paediatr. 82, 352-354.
72. Osterman, M. T., Haynes, K., Delzell, E., Zhang, J., Bewtra, M., Brensinger, C., Chen, L., Xie, F., Curtis, J. R. and Lewis, J. D. (2013) Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin. Gastroenterol. Hepatol., doi:10.1016/j.cgh.2013.06.010.
73. Danese, S. (2013) IBD: Golimumab in ulcerative colitis: a 'menage a trois' of drugs. Nat. Rev. Gastroenterol. Hepatol. 10, 511-512.
74. Ramirez-Herraiz, E., Escudero-Vilaplana, V., Alanon-Plaza, E., Trovato-Lopez, N., Herranz-Alonso, A., Morell-Baladron, A. and Sanjurjo-Saez, M. (2013) Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin. Exp. Rheumatol. 31, 559-565.
75. Rajanayagam, J. and Lewindon, P. J. (2013) Infliximab as rescue therapy in paediatric autoimmune hepatitis. J. Hepatol. 59, 908-909.
76. Chen, D., Wang, X. B., Zhou, Y. and Zhu, X. C. (2013) Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol. Int. 33, 2455-2458.
77. Deeks, E. D. (2013) Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs 73, 75-97.
78. Hamed, H. A., Yamaguchi, Y., Fisher, P. B., Grant, S. and Dent, P. (2013) Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. J. Cell. Physiol. 228, 1996-2005.
79. Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A. and Ford, H. L. (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32, 1341-1350.
80. Moriishi, T., Fukuyama, R., Ito, M., Miyazaki, T., Maeno, T., Kawai, Y., Komori, H. and Komori, T. (2012) Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading. PLoS ONE 7, e40143.
81. Izawa, T., Ishimaru, N., Moriyama, K., Kohashi, M., Arakaki, R. and Hayashi, Y. (2007) Crosstalk between RANKL and Fas signaling in dendritic cells controls immune tolerance. Blood 110, 242-250.
82. Epstein, M. S., Ephros, H. D. and Epstein, J. B. (2012) Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg. Oral Med. Oral. Path Oral Rad. 116, e434-e442.
83. Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu, Y. M., Scott, H., Hession, C., Garcia, I. and Browning, J. L. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272, 32401-32410.
84. Chen, T., Guo, Z. P., Li, L., Li, M. M., Wang, T. T., Jia, R. Z., Cao, N. and Li, J. Y. (2013) TWEAK enhances E-selectin and ICAM-1 expression, and may contribute to the development of cutaneous vasculitis. PLoS ONE 8, e56830.
85. Ucero, A. C., Benito-Martin, A., Fuentes-Calvo, I., Santamaria, B., Blanco, J., Lopez-Novoa, J. M., Ruiz-Ortega, M., Egido, J., Burkly, L. C., Martinez-Salgado, C. and Ortiz, A. (2013) TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim. Biophys. Acta 1832, 1744-1755.
86. Park, J. S., Park, M. K., Lee, S. Y., Oh, H. J., Lim, M. A., Cho, W. T., Kim, E. K., Ju, J. H., Park, Y. W., Park, S. H. et al. (2012) TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine 60, 143-149.
87. Michaelson, J. S., Wisniacki, N., Burkly, L. C. and Putterman, C. (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. J. Autoimmun. 39, 130-142.
88. Mackay, F. and Ambrose, C. (2003) The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev. 14, 311-324.
89. Xiao, Y., Motomura, S., Deyev, V. and Podack, E. R. (2011) TNF superfamily member 13, APRIL, inhibits allergic lung inflammation. Eur. J. Immunol. 41, 164-171.
90. Fernandez, L., Salinas, G. F., Rocha, C., Carvalho-Pinto, C. E., Yeremenko, N., Papon, L., Medema, J. P., Combe, B., Morel, J., Baeten, D. and Hahne, M. (2013) The TNF family member APRIL dampens collagen-induced arthritis. Ann. Rheum. Dis. 72, 1367-1374.
91. Gao, Q., Li, Q., Xue, Z., Wu, P. and Yang, X. (2013) In vitro and in vivo evaluation of a humanized anti-APRIL antibody. Curr. Mol. Med. 13, 464-465.
92. t Hart, B. A., Jagessar, S. A., Haanstra, K., Verschoor, E., Laman, J. D. and Kap, Y. S. (2013) The Primate EAE model points at EBV-infected B Cells as a preferential therapy target in multiple sclerosis. Front. Immunol. 4, 145.
93. MacLennan, I. and Vinuesa, C. (2002) Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 17, 235-238.
94. Lied, G. A. and Berstad, A. (2011) Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand. J. Immunol. 73, 1-7.
95. Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A. and Mackay, F. (2013) The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203-215.
96. Chhabra, M., Conlon, T. M., Saeb-Parsy, K. and Pettigrew, G. J. (2013) BAFF and associated TNF superfamily members in renal transplantation: an end to blysful ignorance. Transplantation 96, 853-859.
97. Croft, M., Duan, W., Choi, H., Eun, S. Y., Madireddi, S. and Mehta, A. (2012) TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol. 33, 144-152.
98. Nadiminty, N., Chun, J. Y., Hu, Y., Dutt, S., Lin, X. and Gao, A. C. (2007) LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem. Biophys. Res. Commun. 359, 379-384.
99. Morel, Y., Truneh, A., Costello, R. T. and Olive, D. (2003) LIGHT, a new TNF superfamily member, is essential for memory T helper cell-mediated activation of dendritic cells. Eur. J. Immunol. 33, 3213-3219.
100. Dinarello, C. A., Marnoy, S. O. and Rosenwasser, L. J. (1983) Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J. Immunol. 130, 890-895.
101. Kobayashi, Y., Yamamoto, K., Saido, T., Kawasaki, H., Oppenheim, J. J. and Matsushima, K. (1990) Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 α. Proc. Natl. Acad. Sci. U.S.A. 87, 5548-5552.
102. Kostura, M. J., Tocci, M. J., Limjuco, G., Chin, J., Cameron, P., Hillman, A. G., Chartrain, N. A. and Schmidt, J. A. (1989) Identification of a monocyte specific pre-interleukin 1 ß convertase activity. Proc. Natl. Acad. Sci. U.S.A. 86, 5227-5231.
103. Ahmad, R., Sylvester, J. and Zafarullah, M. (2007) MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell. Signal. 19, 2549-2557.
104. Elias, J. A., Reynolds, M. M., Kotloff, R. M. and Kern, J. A. (1989) Fibroblast interleukin 1 ß: synergistic stimulation by recombinant interleukin 1 and tumor necrosis factor and posttranscriptional regulation. Proc. Natl. Acad. Sci. U.S.A. 86, 6171-6175.
105. Blech, M., Peter, D., Fischer, P., Bauer, M. M., Hafner, M., Zeeb, M. and Nar, H. (2013) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1ß. J. Mol. Biol. 425, 94-111.
106. Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., Bader-Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D. et al. (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64, 557-567.
107. Krause, K., Mahamed, A., Weller, K., Metz, M., Zuberbier, T. and Maurer, M. (2013) Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J. Allergy Clin. Immunol. 132, 751-754.
108. Ridker, P. M., Thuren, T., Zalewski, A. and Libby, P. (2011) Interleukin-1ß inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605.
109. Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P. et al. (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381, 1905-1915.
110. Lovell, D. J., Giannini, E. H., Reiff, A. O., Kimura, Y., Li, S., Hashkes, P. J., Wallace, C. A., Onel, K. B., Foell, D., Wu, R. et al. (2013) Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum. 65, 2486-2496.
111. Dinarello, C. A., Simon, A. and van der Meer, J. W. (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633-652.
112. McIntyre, K. W., Stepan, G. J., Kolinsky, K. D., Benjamin, W. R., Plocinski, J. M., Kaffka, K. L., Campen, C. A., Chizzonite, R. A. and Kilian, P. L. (1991) Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med. 173, 931-939.
113. Cascavilla, N., Bisceglia, M. and D'Arena, G. (2010) Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial. Int. J. Immunopathol. Pharmacol. 23, 633-636.
114. Alpay, N., Sumnu, A., Caliskan, Y., Yazici, H., Turkmen, A. and Gul, A. (2010) Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol. Int. 32, 3277-3279.
115. Piper, S. C., Ferguson, J., Kay, L., Parker, L. C., Sabroe, I., Sleeman, M. A., Briend, E. and Finch, D. K. (2013) The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells. PLoS ONE 8, e63365.
116. Bachmann, M., Horn, K., Poleganov, M. A., Paulukat, J., Nold, M., Pfeilschifter, J. and Muhl, H. (2006) Interleukin-18 secretion and Th1-like cytokine responses in human peripheral blood mononuclear cells under the influence of the toll-like receptor-5 ligand flagellin. Cell. Microbiol. 8, 289-300.
117. Omoto, Y., Yamanaka, K., Tokime, K., Kitano, S., Kakeda, M., Akeda, T., Kurokawa, I., Gabazza, E. C., Tsutsui, H., Katayama, N. et al. (2010) Granzyme B is a novel interleukin-18 converting enzyme. J. Dermatol. Sci. 59, 129-135.
118. Fujita, K., Ewing, C. M., Isaacs, W. B. and Pavlovich, C. P. (2011) Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 129, 424-432.
119. Shigehara, K., Shijubo, N., Ohmichi, M., Yamada, G., Takahashi, R., Okamura, H., Kurimoto, M., Hiraga, Y., Tatsuno, T., Abe, S. and Sato, N. (2000) Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 162, 1979-1982.
120. Striz, I., Krasna, E., Honsova, E., Lacha, J., Petrickova, K., Jaresova, M., Lodererova, A., Bohmova, R., Valhova, S., Slavcev, A. and Vitko, S. (2005) Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol. Lett 99, 30-35.
121. Tanaka, H., Miyazaki, N., Oashi, K., Teramoto, S., Shiratori, M., Hashimoto, M., Ohmichi, M. and Abe, S. (2001) IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J. Allergy Clin. Immunol. 107, 331-336.
122. Lettesjo, H., Hansson, T., Bergqvist, A., Gronlund, J. and Dannaeus, A. (2005) Enhanced interleukin-18 levels in the peripheral blood of children with coeliac disease. Clin. Exp. Immunol. 139, 138-143.
123. Hultgren, O., Andersson, B., Hahn-Zoric, M. and Almroth, G. (2007) Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis. Autoimmunity 40, 529-531.
124. Altinova, A. E., Yetkin, I., Akbay, E., Bukan, N. and Arslan, M. (2008) Serum IL-18 levels in patients with type 1 diabetes: relations to metabolic control and microvascular complications. Cytokine 42, 217-221.
125. Gangemi, S., Mallamace, A., Minciullo, P. L., Santoro, D., Merendino, R. A., Savica, V. and Bellinghieri, G. (2002) Involvement of interleukin-18 in patients on maintenance haemodialysis. Am. J. Nephrol. 22, 417-421.
126. Tarhini, A. A., Millward, M., Mainwaring, P., Kefford, R., Logan, T., Pavlick, A., Kathman, S. J., Laubscher, K. H., Dar, M. M. and Kirkwood, J. M. (2009) A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859-868.
127. Wang, J., Long, Q., Zhang, W. and Chen, N. (2012) Protective effects of exogenous interleukin 18-binding protein in a rat model of acute renal ischemia-reperfusion injury. Shock 37, 333-340.
128. Fujita, K., Ewing, C. M., Isaacs, W. B. and Pavlovich, C. P. (2011) Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 129, 424-432.
129. Dinarello, C. A. (2005) An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 23, 461-462.
130. Kuchler, A. M., Pollheimer, J., Balogh, J., Sponheim, J., Manley, L., Sorensen, D. R., De Angelis, P. M., Scott, H. and Haraldsen, G. (2008) Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am. J. Pathol. 173, 1229-1242.
131. Pichery, M., Mirey, E., Mercier, P., Lefrancais, E., Dujardin, A., Ortega, N. and Girard, J. P. (2012) Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J. Immunol. 188, 3488-3495.
132. Moussion, C., Ortega, N. and Girard, J. P. (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 3, e3331.
133. Kondo, Y., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Morimoto, M., Hayashi, N., Hoshino, T., Fujimoto, J. and Nakanishi, K. (2008) Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20, 791-800.
134. Allakhverdi, Z., Smith, D. E., Comeau, M. R. and Delespesse, G. (2007) Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179, 2051-2054.
135. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K. and Kita, H. (2008) A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490.
136. Salmond, R. J., Mirchandani, A. S., Besnard, A. G., Bain, C. C., Thomson, N. C. and Liew, F. Y. (2012) IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J. Allergy Clin. Immunol. 130, 1159-1166.
137. Besnard, A. G., Togbe, D., Guillou, N., Erard, F., Quesniaux, V. and Ryffel, B. (2011) IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol. 41, 1675-1686.
138. Komai-Koma, M., Brombacher, F., Pushparaj, P. N., Arendse, B., McSharry, C., Alexander, J., Chaudhuri, R., Thomson, N. C., McKenzie, A. N., McInnes, I. et al. (2012) Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy 67, 1118-1126.
139. Bourgeois, E., Van, L. P., Samson, M., Diem, S., Barra, A., Roga, S., Gombert, J. M., Schneider, E., Dy, M., Gourdy, P. et al. (2009) The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-? production. Eur. J. Immunol. 39, 1046-1055.
140. Yang, Q., Li, G., Zhu, Y., Liu, L., Chen, E., Turnquist, H., Zhang, X., Finn, O. J., Chen, X. and Lu, B. (2011) IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol. 41, 3351-3360.
141. Liu, X., Li, M., Wu, Y., Zhou, Y., Zeng, L. and Huang, T. (2009) Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 386, 181-185.
142. Kim, Y. H., Yang, T. Y., Park, C. S., Ahn, S. H., Son, B. K., Kim, J. H., Lim, D. H. and Jang, T. Y. (2012) Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 67, 183-190.
143. Carrier, Y., Ma, H. L., Ramon, H. E., Napierata, L., Small, C., O'Toole, M., Young, D. A., Fouser, L. A., Nickerson-Nutter, C., Collins, M. et al. (2011) Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 131, 2428-2437.
144. Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schafer, M., Coyle, A. J., Renauld, J. C., Werner, S., Kisielow, J. and Kopf, M. (2012) Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest. 122, 3965-3976.
145. Kolesar, L., Brabcova, E., Thorburn, E., Sekerkova, A., Brabcova, I., Jaresova, M., Viklicky, O. and Striz, I. (2012) Cytokine gene expression profile in monocytic cells after a co-culture with epithelial cells. Immunol. Res. 52, 269-275.
146. Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., Mangelberger, D., Oostingh, G. J., Pfaller, T., Pixner, C., Posselt, G. et al. (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 22, 127-147.
147. Nold, M. F., Nold-Petry, C. A., Zepp, J. A., Palmer, B. E., Bufler, P. and Dinarello, C. A. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11, 1014-1022.
148. Tete, S., Tripodi, D., Rosati, M., Conti, F., Maccauro, G., Saggini, A., Cianchetti, E., Caraffa, A., Antinolfi, P., Toniato, E. et al. (2012) IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int. J. Immunopathol. Pharmacol. 25, 31-38.
149. van de Veerdonk, F. L., Stoeckman, A. K., Wu, G., Boeckermann, A. N., Azam, T., Netea, M. G., Joosten, L. A., van der Meer, J. W., Hao, R., Kalabokis, V. and Dinarello, C. A. (2012) IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Nat.l Acad. Sci. U.S.A. 109, 3001-3005.
150. Horii, Y., Muraguchi, A., Suematsu, S., Matsuda, T., Yoshizaki, K., Hirano, T. and Kishimoto, T. (1988) Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophagedependent synthesis of BSF-2/IL-6 by T cells. J. Immunol. 141, 1529-1535.
151. Striz, I., Mio, T., Adachi, Y., Romberger, D. J. and Rennard, S. I. (1999) Th2-type cytokines modulate IL-6 release by human bronchial epithelial cells. Immunol. Lett. 70, 83-88.
152. Donnelly, R. P., Crofford, L. J., Freeman, S. L., Buras, J., Remmers, E., Wilder, R. L. and Fenton, M. J. (1993) Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-?B activity in monocytes and fibroblasts. J. Immunol. 151, 5603-5612.
153. Rougier, F., Cornu, E., Praloran, V. and Denizot, Y. (1998) IL-6 and IL-8 production by human bone marrow stromal cells. Cytokine 10, 93-97.
154. Riedemann, N. C., Guo, R. F., Hollmann, T. J., Gao, H., Neff, T. A., Reuben, J. S., Speyer, C. L., Sarma, J. V., Wetsel, R. A., Zetoune, F. S. and Ward, P. A. (2004) Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 18, 370-372.
155. Oldford, S. A., Haidl, I. D., Howatt, M. A., Leiva, C. A., Johnston, B. and Marshall, J. S. (2010) A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 185, 7067-7076.
156. Sofi, M. H., Li, W., Kaplan, M. H. and Chang, C. H. (2009) Elevated IL-6 expression in CD4 T cells via PKCθ and NF-κB induces Th2 cytokine production. Mol. Immunol. 46, 1443-1450.
157. Baccam, M. and Bishop, G. A. (1999) Membrane-bound CD154, but not CD40-specific antibody, mediates NF-κB-independent IL-6 production in B cells. Eur. J. Immunol. 29, 3855-3866.
158. Shabo, Y., Lotem, J., Rubinstein, M., Revel, M., Clark, S. C., Wolf, S. F., Kamen, R. and Sachs, L. (1988) The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood 72, 2070-2073.
159. Rabinowich, H., Sedlmayr, P., Herberman, R. B. and Whiteside, T. L. (1993) Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor-α/ß secretion. J. Immunol. 150, 4844-4855.
160. Tormo, A. J., Letellier, M. C., Sharma, M., Elson, G., Crabe, S. and Gauchat, J. F. (2012) IL-6 activates STAT5 in T cells. Cytokine 60, 575-582.
161. Hilbert, D. M., Cancro, M. P., Scherle, P. A., Nordan, R. P., Van Snick, J., Gerhard, W. and Rudikoff, S. (1989) T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells. J. Immunol. 143, 4019-4024.
162. Castell, J. V., Gomez-Lechon, M. J., David, M., Hirano, T., Kishimoto, T. and Heinrich, P. C. (1988) Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232, 347-350.
163. Fleischmann, R. M., Halland, A. M., Brzosko, M., Burgos-Vargas, R., Mela, C., Vernon, E. and Kremer, J. M. (2013) Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J. Rheumatol. 40, 113-126.
164. Buckland, J. (2013) Rheumatoid arthritis: tocilizumab monotherapy and adalimumab monotherapy go head-to-head in RA. Nat. Rev. Rheumatol. 9, 260.
165. Aguilar-Lozano, L., Castillo-Ortiz, J. D., Vargas-Serafin, C., Morales-Torres, J., Sanchez-Ortiz, A., Sandoval-Castro, C., Padilla-Ibarra, J., Hernandez-Cuevas, C. and Ramos-Remus, C. (2013) Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J. Rheumatol. 40, 1069-1073.
166. De Benedetti, F., Brunner, H. I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., Cuttica, R., Ravelli, A., Schneider, R., Woo, P. et al. (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385-2395.
167. Isik, M., Kilic, L., Dogan, I. and Calguneri, M. (2012) Tocilizumab for giant cell arteritis: an amazing result. Rheumatol. Int. 33, 2961-2962.
168. Araki, M., Aranami, T., Matsuoka, T., Nakamura, M., Miyake, S. and Yamamura, T. (2013) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol. 23, 827-831.
169. Fiala, M., Mizwicki, M. T., Weitzman, R., Magpantay, L. and Nishimoto, N. (2013) Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am. J. Neurodeg. Dis. 2, 129-139.
170. Szepietowski, J. C., Nilganuwong, S., Wozniacka, A., Kuhn, A., Nyberg, F., van Vollenhoven, R. F., Bengtsson, A. A., Reich, A., de Vries, D. E., van Hartingsveldt, B. et al. (2013) Phase 1, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 65, 2661-2671.
171. Reichert, J. M. (2013) Antibodies to watch in 2013: Mid-year update. mAbs 5, 513-517.
172. Taga, T. (1997) The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Ann. Med. 29, 63-72.
173. Kasraie, S., Niebuhr, M. and Werfel, T. (2010) Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 65, 712-721.
174. Adachi, Y., Mio, T., Takigawa, K., Striz, I., Romberger, D. J., Robbins, R. A., Spurzem, J. R., Heires, P. and Rennard, S. I. (1997) Mutual inhibition by TGF-ß and IL-4 in cultured human bronchial epithelial cells. Am. J. Physiol. 273, L701-L708.
175. Gonzalez-Navajas, J. M., Lee, J., David, M. and Raz, E. (2012) Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12, 125-135.
176. Benveniste, E. N. and Qin, H. (2007) Type I interferons as anti-inflammatory mediators. Sci. STKE 416, pe70.
177. Striz, I., Mio, T., Adachi, Y., Carnevali, S., Romberger, D. J. and Rennard, S. I. (2000) Effects of interferons a and ? on cytokine production and phenotypic pattern of human bronchial epithelial cells. Int. J. Immunopharmacol. 22, 573-585.
178. Yang, Y. F., Zhao, W., Xia, H. M., Zhong, Y. D., Huang, P. and Wen, J. (2010) Long-term efficacy of interferon a therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Antivir. Res. 85, 361-365.
179. Gibbert, K., Schlaak, J. F., Yang, D. and Dittmer, U. (2013) IFN-α subtypes: distinct biological activities in anti-viral therapy. Br. J. Pharmacol. 168, 1048-1058.
180. Chapman, J., Oser, M., Hockemeyer, J., Weitlauf, J., Jones, S. and Cheung, R. (2011) Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-a and ribavirin therapy: a prospective evaluation. Am. J. Gastroenterol. 106, 2123-2132.
181. Foster, N., Hulme, S. D. and Barrow, P. A. (2003) Induction of antimicrobial pathways during early-phase immune response to Salmonella spp. in murine macrophages: γ interferon (IFN-γ) and upregulation of IFN-γ receptor α expression are required for NADPH phagocytic oxidase gp91-stimulated oxidative burst and control of virulent Salmonella spp. Infect. Immun. 71, 4733-4741.
182. Frasca, L., Nasso, M., Spensieri, F., Fedele, G., Palazzo, R., Malavasi, F. and Ausiello, C. M. (2008) IFN-γ arms human dendritic cells to perform multiple effector functions. J. Immunol. 180, 1471-1481.
183. Giacomini, P., Tecce, R., Gambari, R., Sacchi, A., Fisher, P. B. and Natali, P. G. (1988) Recombinant human IFN-γ, but not IFN-α or IFN-ß, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. J. Immunol. 140, 3073-3081.
184. Kelleher, P., Goodsall, A., Mulgirigama, A., Kunst, H., Henderson, D. C., Wilson, R., Newman-Taylor, A. and Levin, M. (2006) Interferon-? therapy in two patients with progressive chronic pulmonary aspergillosis. Eur. Respir. J. 27, 1307-1310.
185. Cui, D., Huang, G., Yang, D., Huang, B. and An, B. (2013) Efficacy and safety of interferon-? -targeted therapy in Crohn's disease: A systematic review and meta-analysis of randomized controlled trials. Clin. Res. Hepatol. Gastroenterol. 37, 507-513.
186. Ioannidis, I., Ye, F., McNally, B., Willette, M. and Flano, E. (2013) Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J. Virol. 87, 3261-3270.
187. Witte, K., Witte, E., Sabat, R. and Wolk, K. (2010) IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 21, 237-251.
188. Commins, S., Steinke, J. W. and Borish, L. (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol. 121, 1108-1111.
189. Richardson, M. D., Brownlie, C. E. and Shankland, G. S. (1992) Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J. Med. Vet. Mycol. 30, 433-441.
190. + in murine microglia. J. Neuroinflammation 9, 268.
191. Tai, P. C., Sun, L. and Spry, C. J. (1991) Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin. Exp. Immunol. 85, 312-316.
192. Bozinovski, S., Jones, J. E., Vlahos, R., Hamilton, J. A. and Anderson, G. P. (2002) Granulocyte/macrophage-colonystimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFκ B and AP-1 in vivo. J. Biol. Chem. 277, 42808-42814.
193. Vlahos, R., Bozinovski, S., Chan, S. P., Ivanov, S., Lindén, A., Hamilton, J. A. and Anderson, G. P. (2010) Neutralizing granulocyte/macrophage colony-stimulating factor inhibits cigarette smoke-induced lung inflammation Am. J. Respir. Crit. Care Med. 182, 34-40.
194. Gulati, S. C. and Bennett, C. L. (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann. Int. Med. 116, 177-182.
195. Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D., Barbarash, O., Vatutin, M., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D. et al. (2013) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 72, 1445-1452.
196. Tsuji, T., Sugimoto, K., Yanai, T., Takashita, E. and Mori, K. J. (1994) Induction of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) expression in bone marrow and fractionated marrow cell populations by interleukin 3 (IL-3): IL-3-mediated positive feedback mechanisms of granulopoiesis. Growth Factors 11, 71-79.
197. Roberts, A. W. (2005) G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors 23, 33-41.
198. Holowiecki, J., Giebel, S., Krzemien, S., Krawczyk-Kulis, M., Jagoda, K., Kopera, M., Holowiecka, B., Grosicki, S., Hellmann, A., Dmoszynska, A. et al. (2002) G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk. Lymphoma 43, 315-325.
199. Shim, W., Mehta, A., Lim, S. Y., Zhang, G., Lim, C. H., Chua, T. and Wong, P. (2011) G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc. Res. 89, 20-30.
200. Wildbaum, G., Shahar, E., Katz, R., Karin, N., Etzioni, A. and Pollack, S. (2013) Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: Complete clinical remission with restoration of IL-17 secretion. J. Allergy Clin. Immunol. 132, 761-764.
201. Nomiyama, H., Osada, N. and Yoshie, O. (2013) Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes Cells 18, 1-16.
202. Blanchet, X., Langer, M., Weber, C., Koenen, R. R. and von Hundelshausen, P. (2012) Touch of chemokines. Front. Immunol. 3, 175.
203. De Vries, M. E., Hosiawa, K. A., Cameron, C. M., Bosinger, S. E., Persad, D., Kelvin, A. A., Coombs, J. C., Wang, H., Zhong, R., Cameron, M. J. and Kelvin, D. J. (2003) The role of chemokines and chemokine receptors in alloantigen-independent and alloantigen-dependent transplantation injury. Semin. Immunol. 15, 33-48.
204. Yun, J. J., Fischbein, M. P., Whiting, D., Irie, Y., Fishbein, M. C., Burdick, M. D., Belperio, J., Strieter, R. M., Laks, H., Berliner, J. A. and Ardehali, A. (2002) The role of MIG/CXCL9 in cardiac allograft vasculopathy. Am. J. Pathol. 161, 1307-1313.
205. Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N. and Jones, S. A. (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14, 705-714.
206. Owen, J. L. and Mohamadzadeh, M. (2013) Macrophages and chemokines as mediators of angiogenesis. Front. Physiol. 4, 159.
207. Sahin, H. and Wasmuth, H. E. (2013) Chemokines in tissue fibrosis. Biochim. Biophys. Acta 1832, 1041-1048.
208. Viola, A., Sarukhan, A., Bronte, V. and Molon, B. (2012) The pros and cons of chemokines in tumor immunology. Trends Immunol. 33, 496-504.
209. Allegretti, M., Cesta, M. C., Garin, A. and Proudfoot, A. E. (2012) Current status of chemokine receptor inhibitors in development. Immunol. Lett. 145, 68-78.
210. Henrich, T. J. and Kuritzkes, D. R. (2013) HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virology 3, 51-57.
211. De Blasio, A., Rossi, L., Zappone, E., Ortu La Barbera, E., Salvatori, R., Pacilli, M., Carbone, A., Zaccarelli, E., Papa, A. and Tomao, S. (2013) Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy. Anticancer Drugs 24, 653-657.
212. Keshav, S., Vanasek, T., Niv, Y., Petryka, R., Howaldt, S., Bafutto, M., Racz, I., Hetzel, D., Nielsen, O. H., Vermeire, S. et al. (2013) A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS ONE 8, e60094.
213. + T-cell subsets. Immunol. Rev. 252, 5-11.
214. + T-cell subsets and host defense in the lung. Immunol. Rev. 252, 156-163.
215. Akdis, M., Palomares, O., van de Veen, W., van Splunter, M. and Akdis, C. A. (2012) TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. J. Allergy Clin. Immunol. 129, 1438-1449.
216. Lyakh, L., Trinchieri, G., Provezza, L., Carra, G. and Gerosa, F. (2008) Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol. Rev. 226, 112-131.
217. Ghalib, H. W., Whittle, J. A., Kubin, M., Hashim, F. A., el-Hassan, A. M., Grabstein, K. H., Trinchieri, G. and Reed, S. G. (1995) IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154, 4623-4629.
218. + effector memory T cells in vivo. Blood 118, 3890-3900.
219. Hamza, T., Barnett, J. B. and Li, B. (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int. J. Mol. Sci. 11, 789-806.
220. Bryan, S. A., O'Connor, B. J., Matti, S., Leckie, M. J., Kanabar, V., Khan, J., Warrington, S. J., Renzetti, L., Rames, A., Bock, J. A. et al. (2000) Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2149-2153.
221. Wang, Y., Fan, K. T., Li, J. M. and Waller, E. K. (2012) The regulation and activity of interleukin-12. Front. Biosci. 4, 888-899.
222. Li, Z., Wu, F., Brant, S. R. and Kwon, J. H. (2011) IL-23 receptor regulation by Let-7f in human CD4+ memory T cells. J. Immunol. 186, 6182-6190.
223. McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M. et al. (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780-789.
224. Konijeti, G. G. and Chan, A. T. (2013) Ustekinumab for moderate-to-severe Crohn's disease. Gastroenterology 144, 846-848.
225. Hall, A. O., Beiting, D. P., Tato, C., John, B., Oldenhove, G., Lombana, C. G., Pritchard, G. H., Silver, J. S., Bouladoux, N., Stumhofer, J. S. et al. (2012) The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 37, 511-523.
226. Wojno, E. D. and Hunter, C. A. (2012) New directions in the basic and translational biology of interleukin-27. Trends Immunol. 33, 91-97.
227. Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S. and Vignali, D. A. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569.
228. Whitehead, G. S., Wilson, R. H., Nakano, K., Burch, L. H., Nakano, H. and Cook, D. N. (2012) IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J. Allergy Clin. Immunol. 129, 207-215.
229. + T cells correlate with disease activity in rheumatoid arthritis. Mod. Rheumatol., doi: 10.1007/s10165-013-0879-y.
230. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K. (2009) IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517.
231. Zhu, S. and Qian, Y. (2012) IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin. Sci. 122, 487-511.
232. Loverre, A., Tataranni, T., Castellano, G., Divella, C., Battaglia, M., Ditonno, P., Corcelli, M., Mangino, M., Gesualdo, L., Schena, F. P. and Grandaliano, G. (2011) IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibody-mediated rejection. Am. J. Transplant. 11, 1248-1259.
233. Patel, D. D., Lee, D. M., Kolbinger, F. and Antoni, C. (2013) Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72 (Suppl. 2), ii116-ii123.
234. Chiricozzi, A. and Krueger, J. G. (2013) IL-17 targeted therapies for psoriasis. Expert Opin. Investig. Drugs 22, 993-1005.
235. Fitzpatrick, L. R. (2013) Inhibition of IL-17 as a Pharmacological Approach for IBD. Int. Rev. Immunol. 32, 544-555.
236. Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J. et al. (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12, 1159-1166.
237. Starnes, T., Broxmeyer, H. E., Robertson, M. J. and Hromas, R. (2002) Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J. Immunol. 169, 642-646.
238. Suzukawa, M., Morita, H., Nambu, A., Arae, K., Shimura, E., Shibui, A., Yamaguchi, S., Suzukawa, K., Nakanishi, W., Oboki, K. et al. (2012) Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma. J. Immunol. 189, 3641-3652.
239. Song, X. and Qian, Y. (2013) The activation and regulation of IL-17 receptor mediated signaling. Cytokine 62, 175-182.
240. Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y. H., Schluns, K. S., Broaddus, R. R., Zhu, Z. and Dong, C. (2008) Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205, 1063-1075.
241. c family cytokines. Nat. Rev. Immunol. 9, 480-490.
242. Shalapour, S., Deiser, K., Kuhl, A. A., Glauben, R., Krug, S. M., Fischer, A., Sercan, O., Chappaz, S., Bereswill, S., Heimesaat, M. M. et al. (2012) Interleukin-7 links T lymphocyte and intestinal epithelial cell homeostasis. PLoS ONE 7, e31939.
243. Takai, T. (2012) TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol. Int. 61, 3-17.
244. Uller, L., Leino, M., Bedke, N., Sammut, D., Green, B., Lau, L., Howarth, P. H., Holgate, S. T. and Davies, D. E. (2010) Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-ß in bronchial epithelial cells from donors with asthma. Thorax 65, 626-632.
245. Chen, Z. G., Zhang, T. T., Li, H. T., Chen, F. H., Zou, X. L., Ji, J. Z. and Chen, H. (2013) Neutralization of TSLP inhibits airway remodeling in a murine model of allergic asthma induced by chronic exposure to house dust mite. PLoS ONE 8, e51268.
246. Perera, P. Y., Lichy, J. H., Waldmann, T. A. and Perera, L. P. (2012) The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 14, 247-261.
247. Vasakova, M., Sterclova, M., Kolesar, L., Slavcev, A., Pohunek, P., Sulc, J. and Striz, I. (2009) Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. Respir. Med. 103, 773-779.
248. Cinek, O., Vavrincova, P., Striz, I., Drevinek, P., Sedlakova, P., Vavrinec, J. and Slavcev, A. (2004) Association of single nucleotide polymorphisms within cytokine genes with juvenile idiopathic arthritis in the Czech population. J. Rheumatol. 31, 1206-1210.
249. Savan, R., Ravichandran, S., Collins, J. R., Sakai, M. and Young, H. A. (2009) Structural conservation of interferon ? among vertebrates. Cytokine Growth Factor Rev. 20, 115-124.
250. Enk, C. D., Sredni, D., Blauvelt, A. and Katz, S. I. (1995) Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J. Immunol. 154, 4851-4856.
251. O'Keefe, G. M., Nguyen, V. T. and Benveniste, E. N. (1999) Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-ß, IL-4, IL-13 and IL-10. Eur. J. Immunol. 29, 1275-1285.
252. Itoh, K. and Hirohata, S. (1995) The role of IL-10 in human B cell activation, proliferation, and differentiation. J. Immunol. 154, 4341-4350.
253. Anon (1999) Interleukin-10. Cytokine synthesis inhibitory factor, SCH 52000, rIL-10, rhIL-10. Drugs R D 1, 262-264.
254. Smeets, T. J., Kraan, M. C., Versendaal, J., Breedveld, F. C. and Tak, P. P. (1999) Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J. Rheumatol. 26, 2089-2093.
255. Azuma, Y. T., Nakajima, H. and Takeuchi, T. (2011) IL-19 as a potential therapeutic in autoimmune and inflammatory diseases. Curr. Pharm. Des. 17, 3776-3780.
256. Alanara, T., Karstila, K., Moilanen, T., Silvennoinen, O. and Isomaki, P. (2010) Expression of IL-10 family cytokines in rheumatoid arthritis: elevated levels of IL-19 in the joints. Scand. J. Rheumatol. 39, 118-126.
257. Pace, E., Scafidi, V., Di Bona, D., Siena, L., Chiappara, G., Ferraro, M., La Grutta, S., Gallina, S., Speciale, R., Ballacchino, A. et al. (2012) Increased expression of IL-19 in the epithelium of patients with chronic rhinosinusitis and nasal polyps. Allergy 67, 878-886.
258. Lebre, M. C., Jonckheere, C. L., Kraan, M. C., van Kuijk, A. W. R., Bos, J. D., de Rie, M., Gerlag, D. M. and Tak, P. P. (2012) Expression of IL-20 in lesional skin and synovium of patients with psoriatic arthritis compared to rheumatoid arthritis and its response to alefacept treatment. Arthritis Res. Ther. 14, R200.
259. Kragstrup, T. W., Otkjaer, K., Hohn, C., Jorgensen, A., Hokland, M., Iversen, L. and Deleuran, B. (2008) The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 41, 16-23.
260. Wei, C. C., Hsu, Y. H., Li, H. H., Wang, Y. C., Hsieh, M. Y., Chen, W. Y., Hsing, C. H. and Chang, M. S. (2006) IL-20: biological functions and clinical implications. J. Biomed. Sci. 13, 601-612.
261. + T lymphocytes. Cell. Res. 16, 902-907.
262. Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S. T., Otte, J. M., Diepolder, H., Marquardt, A., Jagla, W., Popp, A. et al. (2006) IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838.
263. Radaeva, S., Sun, R., Pan, H. N., Hong, F. and Gao, B. (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332-1342.
264. Sonnenberg, G. F., Fouser, L. A. and Artis, D. (2011) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383-390.
265. Wang, M. and Liang, P. (2005) Interleukin-24 and its receptors. Immunology 114, 166-170.
266. Poindexter, N. J., Williams, R. R., Powis, G., Jen, E., Caudle, A. S., Chada, S. and Grimm, E. A. (2010) IL-24 is expressed during wound repair and inhibits TGFα-induced migration and proliferation of keratinocytes. Exp. Dermatol. 19, 714-722.
267. Margue, C. and Kreis, S. (2010) IL-24: physiological and supraphysiological effects on normal and malignant cells. Curr. Med. Chem. 17, 3318-3326.
268. Donnelly, R. P., Sheikh, F., Dickensheets, H., Savan, R., Young, H. A. and Walter, M. R. (2010) Interleukin-26: An IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev. 21, 393-401.
269. Cella, M., Otero, K. and Colonna, M. (2010) Expansion of human NK-22 cells with IL-7, IL-2, and IL-1 ß reveals intrinsic functional plasticity. Proc. Natl. Acad. Sci. U.S.A. 107, 10961-10966.
270. Doerner, A. M. and Zuraw, B. L. (2009) TGF-ß1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL-1ß but not abrogated by corticosteroids. Respir. Res. 10, 100.
271. Werner, F., Jain, M. K., Feinberg, M. W., Sibinga, N. E., Pellacani, A., Wiesel, P., Chin, M. T., Topper, J. N., Perrella, M. A. and Lee, M. E. (2000) Transforming growth factor-ß 1 inhibition of macrophage activation is mediated via Smad3. J. Biol. Chem. 275, 36653-36658.
272. Taylor, A. W. (2009) Review of the activation of TGF-ß in immunity. J. Leukoc. Biol. 85, 29-33.
273. Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. and Flavell, R. A. (2006) Transforming growth factor-ß regulation of immune responses. Ann. Rev. Immunol. 24, 99-146.
274. Santibanez, J. F., Quintanilla, M. and Bernabeu, C. (2011) TGF-ß/TGF-ß receptor system and its role in physiological and pathological conditions. Clin. Sci. 121, 233-251.
275. Li, M. O., Sanjabi, S. and Flavell, R. A. (2006) Transforming growth factor-ß controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25, 455-471.
276. Meng, X. M., Chung, A. C. and Lan, H. Y. (2013) Role of the TGF-ß/BMP-7/Smad pathways in renal diseases. Clin. Sci. 124, 243-254.
277. Halwani, R., Al-Muhsen, S., Al-Jahdali, H. and Hamid, Q. (2011) Role of transforming growth factor-ß in airway remodeling in asthma. Am. J. Respir. Cell. Mol. Biol. 44, 127-133.
278. Tatler, A. L. and Jenkins, G. (2012) TGF-ß activation and lung fibrosis. Proc. Am. Thorac. Soc. 9, 130-136.
279. Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K. et al. (2011) A phase 1, single-dose study of fresolimumab, an anti-TGF-ß antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243.
280. Lonning, S., Mannick, J. and McPherson, J. M. (2011) Antibody targeting of TGF-ß in cancer patients. Curr. Pharm. Biotech. 12, 2176-2189.
281. Licona-Limon, P. and Soldevila, G. (2007) The role of TGF-ß superfamily during T cell development: new insights. Immunol. Lett. 109, 1-12.
282. Sierra-Filardi, E., Puig-Kroger, A., Blanco, F. J., Nieto, C., Bragado, R., Palomero, M. I., Bernabeu, C., Vega, M. A. and Corbi, A. L. (2011) Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 117, 5092-5101.
283. Beenken, A. and Mohammadi, M. (2009) The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235-253.
284. Heine, G. H., Seiler, S. and Fliser, D. (2012) FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol. Dial. Transplant. 27, 3072-3081.
285. Andrae, J., Gallini, R. and Betsholtz, C. (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22, 1276-1312.
286. Attar, M. A., Salem, J. C., Pursel, H. S. and Santy, L. C. (2012) CNK3 and IPCEF1 produce a single protein that is required for HGF dependent Arf6 activation and migration. Exp. Cell Res. 318, 228-237.
287. Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K. A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D. et al. (2009) Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009-8016.
288. Shaik-Dasthagirisaheb, Y. B., Varvara, G., Murmura, G., Saggini, A., Potalivo, G., Caraffa, A., Antinolfi, P., Tete, S., Tripodi, D., Conti, F. et al. (2013) Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int. J. Immunopathol. Pharmacol. 26, 327-335.
289. Ahluwalia, A., Jones, M. K., Szabo, S. and Tarnawski, A. S. (2013) Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. Biochem. Biophys. Res. Commun. 437, 515-520.
290. Saif, M. W. (2013) Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer? Anticancer Res. 33, 2377-2380.
291. Pirker, R. (2013) EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target. Oncol. 8, 47-53.
292. Berardi, R., Santoni, M., Morgese, F., Ballatore, Z., Savini, A., Onofri, A., Mazzanti, P., Pistelli, M., Pierantoni, C., De Lisa, M. et al. (2013) Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco. Targets Ther. 6, 563-576.